Alpha 2.0
Login Register
» Authors » Andrea Fagiolini

Andrea Fagiolini

Explore the profile of Andrea Fagiolini including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 308
Citations 3970
Followers 0
Related Specialties
Psychiatry
Pharmacology
Neurology
Top 10 Co-Authors
Alessandro Cuomo
Ellen Frank
Arianna Goracci
David J Kupfer
Giuseppe Maina
Letizia Bossini
Eduard Vieta
Paola Rucci
Simone Bolognesi
Eugenio Aguglia
Published In
Riv Psichiatr
Ann Gen Psychiatry
Bipolar Disord
J Clin Psychiatry
Expert Opin Pharmacother
Affiliations
Soon will be listed here.
Recent Articles
1.
Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine
Cuomo A, Forleo G, Ghodhbane T, Johnsen J, Montejo A, Oliveira C, et al.
Ann Gen Psychiatry . 2025 Mar; 24(1):13. PMID: 40075512
Background: Schizophrenia is a highly heterogeneous disease, and a high percentage of patients are at high risk of developing somatic comorbidities, which must be taken into account in disease management...
2.
Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals
Fagiolini A, Leopold K, Pappa S, Cottam W, Hickey J, Rogerson O, et al.
Adv Ther . 2025 Mar; PMID: 40025389
Introduction: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM 400 two-injection start initiation regimen (AOM 400-TIS) is...
3.
Symptom modulation and tolerability of intravenous ketamine in treatment-resistant bipolar depression: A retrospective study
Cuomo A, Pardossi S, Barilla G, Carmellini P, Firenzuoli B, Tarantino F, et al.
J Affect Disord . 2025 Feb; 376:76-83. PMID: 39904464
Ketamine's use in treating bipolar depression must account for risks, such as switching to manic episodes or worsening symptoms. This study examines ketamine's impact on depressive symptoms, focusing on 'inner...
4.
A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole
Fagiolini A, Wang Y, Bioque M, Harlin M, Larsen F, Wang X, et al.
Curr Med Res Opin . 2025 Jan; 41(2):317-327. PMID: 39871633
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized...
5.
Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review
Fagiolini A, Cuomo A, de Berardis D, DellOsso B, Pompili M, Serafini G
Int Clin Psychopharmacol . 2025 Jan; PMID: 39835836
Schizophrenia is a serious psychiatric condition requiring continuous treatment with antipsychotic medications available in different formulations, including oral antipsychotics (OAPs) and long-acting injectables (LAIs). This narrative review aims to comprehensively...
6.
Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features
Carmellini P, Cuomo A, Pierini C, Pardossi S, Pinzi M, Mariantoni E, et al.
Int Clin Psychopharmacol . 2025 Jan; PMID: 39819774
Psychomotor agitation is a challenging symptom of major depressive disorder with mixed features (MDD-MF), often worsening outcomes and complicating treatment. This retrospective study assessed the efficacy and tolerability of intravenous...
7.
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder
Trovini G, Lombardozzi G, Kotzalidis G, Pagano I, Amici E, Giovanetti V, et al.
Curr Neuropharmacol . 2025 Jan; PMID: 39819543
Introduction/objective: Schizophrenia with substance use disorder is a complex clinical condition that may increase treatment resistance. Cannabis use disorder is frequently associated with psychosis and the causal link has still...
8.
Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: insights from real-world clinical settings
Agnorelli C, Cinti A, Barilla G, Lomi F, Scoccia A, Benelli A, et al.
Mol Psychiatry . 2025 Jan; PMID: 39809847
Ketamine, a dissociative compound, shows promise in treating mood disorders, including treatment-resistant depression (TRD) and bipolar disorder (BD). Despite its therapeutic potential, the neurophysiological mechanisms underlying ketamine's effects are not...
9.
Therapeutic Potential of Saffron Extract in Mild Depression: A Study of Its Role on Anhedonia in Rats and Humans
Corridori E, Salviati S, Demontis M, Vignolini P, Vita C, Fagiolini A, et al.
Phytother Res . 2025 Jan; 39(3):1277-1291. PMID: 39754520
Drugs generally used in major depressive disorder are considered inappropriate for the more common milder forms. The efficacy of saffron extracts has been demonstrated in mild to moderate depression and...
10.
Association between a large change between the minimum and maximum monthly values of solar insolation and a history of suicide attempts in bipolar I disorder
Ritter P, Glenn T, Achtyes E, Alda M, Agaoglu E, Altinbas K, et al.
Int J Bipolar Disord . 2024 Dec; 12(1):43. PMID: 39714599
Background: The rate of suicide attempts by patients with bipolar disorder is high. In addition to patient and country specific factors, environmental factors may contribute to suicidal behavior. Sunlight has...